Both trials met their co-primary endpoints, demonstrating significant improvements in nasal polyp scores and nasal obstruction over 52 weeks compared to the placebo, according to an Oct. 14 news release from the company.
The condition, CRSwNP, causes significant symptoms including nasal obstruction and loss of smell, with 40% of cases being uncontrolled.
Depemokimab targets interleukin-5, a key cytokine linked to type 2 inflammation, which is prevalent in nasal polyp tissue.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
